• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

(R)-Equol

(R)-Equol ((+)-Equol) 是一种 ERα (Ki:27.4 nM) 和 Erβ (Ki:15.4 nM) 激动剂。

CAS号

221054-79-1

分子式

C15H14O3

主要靶点

Estrogen/progestogen Receptor

仅限科研使用

Cat No : CM04011

Print datasheet

Synonyms

R-雌马酚|(+)-Equol

验证数据展示

  • CAS No.: 221054-79-1

    (R)-Equol
    CAS#: 221054-79-1

产品信息

(R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.

CAS号 221054-79-1
分子式 C15H14O3
主要靶点 Estrogen/progestogen Receptor
主要通路 内分泌与激素
分子量 242.2699
纯度 99.04%， 此纯度可做参考，具体纯度与批次有关系，可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
别名 R-雌马酚|(+)-Equol

靶点活性

ERβ:15.4 nM (Ki)|ERα:27.4 nM (Ki)

体内活性

In Animals, (R)-Equol has a significantly reduced number of palpable tumors over time when compared with Controls (P=0.002).In addition, the number of palpable tumors formed by each rat in the (R)-Equol fed group was significantly lower than that of rats treated with S-(-)equol (P = 0.008). (R)-Equol-fed animals have 43% fewer tumors than the control group and this difference is highly statistically significant (P=0.004). The number of tumors/tumor-bearing animals is significantly lower in the animals fed (R)-Equol compare with Controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) when compared with Controls (9.9±1.4 mg). Feeding the (R)-Equol diet results in significantly increased tumor latency (P=0.003) [3].

体外活性

(R)-Equol produced a dose-dependent inhibitory effect on the invasive ability of MDA-MB-231 cells, and this inhibitory effect was obvious at the highest test concentration (50 μM).Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035) [2].

溶解度

DMSO:100 mg/mL (412.76 mM),Sonification/heating is recommended.

参考文献

1.Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
2.Magee PJ, et al. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr. 2014 Feb;53(1):345-50.
3.Brown NM, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis. 2010 May;31(5):886-93.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2